Jump Financial LLC Has $6.73 Million Stock Holdings in PROCEPT BioRobotics Corporation $PRCT

Key Points

• Jump Financial LLC increased its holdings in PROCEPT BioRobotics by 131.5%, now owning approximately 115,434 shares valued at $6.725 million.
• PROCEPT BioRobotics reported a quarterly revenue of $79.18 million, exceeding analysts' expectations and marking a 48.3% increase compared to the same quarter last year.
• Brokerages have given PRCT a mixed response, with seven analysts rating it as a Buy and two as a Hold, while price targets range from $55 to $74.88.

Jump Financial LLC grew its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 131.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 115,434 shares of the company's stock after purchasing an additional 65,569 shares during the quarter. Jump Financial LLC owned about 0.21% of PROCEPT BioRobotics worth $6,725,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd acquired a new stake in shares of PROCEPT BioRobotics in the first quarter valued at about $30,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of PROCEPT BioRobotics in the first quarter valued at about $40,000. CWM LLC grew its position in shares of PROCEPT BioRobotics by 69.5% in the first quarter. CWM LLC now owns 873 shares of the company's stock valued at $51,000 after purchasing an additional 358 shares during the last quarter. Nisa Investment Advisors LLC grew its position in shares of PROCEPT BioRobotics by 32.5% in the first quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company's stock valued at $64,000 after purchasing an additional 270 shares during the last quarter. Finally, IFP Advisors Inc grew its position in shares of PROCEPT BioRobotics by 358.9% in the first quarter. IFP Advisors Inc now owns 3,313 shares of the company's stock valued at $193,000 after purchasing an additional 2,591 shares during the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ:PRCT traded down $0.46 during trading on Thursday, reaching $40.34. The stock had a trading volume of 688,365 shares, compared to its average volume of 1,016,891. PROCEPT BioRobotics Corporation has a 52 week low of $37.12 and a 52 week high of $103.81. The business's 50-day moving average price is $51.42 and its 200 day moving average price is $56.06. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.21 and a quick ratio of 7.86. The stock has a market capitalization of $2.24 billion, a PE ratio of -26.03 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.06. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. The firm had revenue of $79.18 million during the quarter, compared to analysts' expectations of $75.67 million. During the same quarter in the previous year, the company posted ($0.50) EPS. PROCEPT BioRobotics's revenue was up 48.3% on a year-over-year basis. As a group, equities analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Antal Rohit Desai sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $61.49, for a total value of $1,537,250.00. Following the completion of the transaction, the director owned 14,363 shares in the company, valued at $883,180.87. The trade was a 63.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders have sold 100,000 shares of company stock valued at $6,271,250. Insiders own 6.60% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company decreased their target price on PROCEPT BioRobotics from $75.00 to $58.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Morgan Stanley decreased their target price on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 15th. Oppenheimer began coverage on shares of PROCEPT BioRobotics in a research note on Monday, July 7th. They set a "market perform" rating for the company. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Stephens began coverage on shares of PROCEPT BioRobotics in a research note on Wednesday, July 9th. They set an "overweight" rating and a $70.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and an average price target of $74.88.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).